Cartilage damage in the knee affects millions of people worldwide with a continued rise in incidence. Currently, the only conventional solutions are symptoms (pain, stiffness) management, microfracture and in the end, replacing the joint with a prosthesis. Lately, cell therapies have emerged as a solution to regenerate cartilage e.g. tissue engineered autologous chondrocyte implantations (ACIs). However, ACIs often fail to integrate with the surrounding tissue, which results in failure rates up to 36%. Lamina’s new cell therapy from the Strasbourg University and Inserm aims to improve the cell approach by an innovative scaffold that houses Mesenchymal stem cells (MSCs) for optimal regeneration of the cartilage. By combining this patented scaffold together with growth factors and the MSCs, the product ensures fast recovery and high quality cartilage.
Recent news
INTRODUCING LIFTYA: STABILITY WITH MOTION
PRESS RELEASE Amsterdam, 05/12/2023 Liftya is a bracing solution that preserves the range of motion, improving the rehabilitation and quality of life of patients…
Read more
MLA Diagnostics secures a 7-figure funding round
PRESS RELEASE Maastricht, November 2023 Dutch start-up MLA Diagnostics, on a mission to improve tailored treatments for skin cancer patients, secures funding for continued…
Read more
INTRODUCING AXIAL ORTHOPAEDICS INC: A differentiated intramedullary nailing system
PRESS RELEASE November 27, 2023 Axial Orthopaedics Inc. offers a differentiated design of an intramedullary nailing system, targeting the complex surgeries of 1.2 million…
Read more